country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-187547

Copy Link Print Information

PI3K-IN-64

PI3K-IN-64 is an orally effective phosphoinositide 3-kinase (PI3K) inhibitor. PI3K-IN-64 inhibits tumor growth in vivo. PI3K-IN-64 produces synergistic effects when combined with Fulvestrant (HY-13636) and Palbociclib (HY-50767). PI3K-IN-64 can be used for research on breast cancer.

For research use only. We do not sell to patients.

CAS No.: 2810801-22-8
Formula: C₁₉H₂₂F₂N₆O₄
Molecular Weight:436.41

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

PI3K-IN-64 Chemical Structure

CAS No.: 2810801-22-8

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All PI3K Isoforms :

In Vivo

Anti-cancer

PI3K-IN-64 (Compound 1) (25 mg/kg; p.o.; once daily; 4 weeks) shows potent antitumor activity in the MCF-7 breast cancer xenograft model and exhibits synergistic effects in combination with Fulvestrant (HY-13636) and Palbociclib (HY-50767)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

BALB/c nude mice (female, 6-8 weeks old, 18-20 g, MCF-7 xenograft model)^[1]
Dosage:

25 mg/kg (monotherapy); 25 mg/kg (combination with Fulvestrant); 25 mg/kg (triple combination with Fulvestrant and Palbociclib)
Administration:

p.o.; once daily; 4 weeks
Result:

Inhibited tumor growth in the MCF-7 xenograft model with a mean tumor volume of 148 mm³ at D28, RTV of 0.90, T/C of 29.15%, and TGI of 105.83% as monotherapy.
Inhibited tumor growth in combination with Fulvestrant with a mean tumor volume of 102 mm³, RTV of 0.60, T/C of 19.56%, and TGI of 118.89%.
Inhibited tumor growth in triple combination with Fulvestrant and Palbociclib with a mean tumor volume of 42 mm³, RTV of 0.26, T/C of 8.31%, and TGI of 136.02%.

Related Protocols :

Chemical Information

CAS No. 2810801-22-8
Molecular Weight 436.41
Formula C₁₉H₂₂F₂N₆O₄
SMILES

CO/N=C([C@@H](NC1=CC=C(C2=NC(N3[C@H](C(F)F)COC3=O)=CN2CCO4)C4=C1)C)\N
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Li, Y., et al. Combination of PI3K Inhibitor and Endocrine Therapeutic Drug and Use Thereof. WO 2026/124456 A1, 2026.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote